- Home
- FHTX vs SMBK Comparison
FHTX vs SMBK Comparison
Compare FHTX & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- SMBK
- Stock Information
- Founded
- FHTX 2015
- SMBK N/A
- Country
- FHTX United States
- SMBK United States
- Employees
- FHTX N/A
- SMBK N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- SMBK Major Banks
- Sector
- FHTX Health Care
- SMBK Finance
- Exchange
- FHTX Nasdaq
- SMBK Nasdaq
- Market Cap
- FHTX 513.7M
- SMBK 611.7M
- IPO Year
- FHTX 2020
- SMBK N/A
- Fundamental
- Price
- FHTX $7.72
- SMBK $36.10
- Analyst Decision
- FHTX Strong Buy
- SMBK Buy
- Analyst Count
- FHTX 5
- SMBK 5
- Target Price
- FHTX $16.00
- SMBK $28.20
- AVG Volume (30 Days)
- FHTX 131.6K
- SMBK 62.4K
- Earning Date
- FHTX 11-04-2024
- SMBK 10-21-2024
- Dividend Yield
- FHTX N/A
- SMBK 0.88%
- EPS Growth
- FHTX N/A
- SMBK N/A
- EPS
- FHTX N/A
- SMBK 1.93
- Revenue
- FHTX $25,515,000.00
- SMBK $159,196,000.00
- Revenue This Year
- FHTX N/A
- SMBK N/A
- Revenue Next Year
- FHTX $8.77
- SMBK $12.25
- P/E Ratio
- FHTX N/A
- SMBK $18.66
- Revenue Growth
- FHTX N/A
- SMBK 2.18
- 52 Week Low
- FHTX $2.70
- SMBK $19.00
- 52 Week High
- FHTX $10.25
- SMBK $37.72
- Technical
- Relative Strength Index (RSI)
- FHTX 42.02
- SMBK 65.61
- Support Level
- FHTX $7.33
- SMBK $35.12
- Resistance Level
- FHTX $9.33
- SMBK $36.58
- Average True Range (ATR)
- FHTX 0.72
- SMBK 0.89
- MACD
- FHTX -0.13
- SMBK -0.12
- Stochastic Oscillator
- FHTX 16.46
- SMBK 70.29
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.